141 related articles for article (PubMed ID: 7486914)
1. Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice.
Roehrborn AA; Hansbrough JF; Gualdoni B; Kim S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1752-5. PubMed ID: 7486914
[TBL] [Abstract][Full Text] [Related]
2. Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus.
Murillo O; Pachón ME; Euba G; Verdaguer R; Carreras M; Cabellos C; Cabo J; Gudiol F; Ariza J
J Antimicrob Chemother; 2009 Nov; 64(5):1062-6. PubMed ID: 19744977
[TBL] [Abstract][Full Text] [Related]
3. Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.
Jennings JA; Carpenter DP; Troxel KS; Beenken KE; Smeltzer MS; Courtney HS; Haggard WO
Clin Orthop Relat Res; 2015 Jul; 473(7):2270-82. PubMed ID: 25604874
[TBL] [Abstract][Full Text] [Related]
4. Antibiotics delivered by an implantable drug pump. A new application for treating osteomyelitis.
Perry CR; Ritterbusch JK; Rice SH; Davenport K; Burdge RE
Am J Med; 1986 Jun; 80(6B):222-7. PubMed ID: 3728532
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylcholine Coatings Deliver Local Antimicrobials and Reduce Infection in a Murine Model: A Preliminary Study.
Harris MA; Beenken KE; Smeltzer MS; Haggard WO; Jennings JA
Clin Orthop Relat Res; 2017 Jul; 475(7):1847-1853. PubMed ID: 28050817
[TBL] [Abstract][Full Text] [Related]
6. Absorbable, delayed-release antibiotic beads reduce surgical wound infection.
Galandiuk S; Wrightson WR; Young S; Myers S; Polk HC
Am Surg; 1997 Sep; 63(9):831-5. PubMed ID: 9290532
[TBL] [Abstract][Full Text] [Related]
7. Local treatment of prosthetic vascular graft infection with multivesicular liposome-encapsulated amikacin.
Huh J; Chen JC; Furman GM; Malki C; King B; Kafie F; Wilson SE
J Surg Res; 1998 Jan; 74(1):54-8. PubMed ID: 9536974
[TBL] [Abstract][Full Text] [Related]
8. Solvent-free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone--an in vivo study.
Peng YJ; Kau YC; Wen CW; Liu KS; Liu SJ
J Biomed Mater Res A; 2010 Aug; 94(2):426-32. PubMed ID: 20186737
[TBL] [Abstract][Full Text] [Related]
9. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.
Leitzke S; Bucke W; Borner K; Müller R; Hahn H; Ehlers S
Antimicrob Agents Chemother; 1998 Feb; 42(2):459-61. PubMed ID: 9527808
[TBL] [Abstract][Full Text] [Related]
10. The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound.
Hurtuk MG; He LK; Szilagyi A; Gamelli RL; Hecht DW; Kennedy RH; Rhys-Williams W; Love WG; Shankar R
J Burn Care Res; 2010; 31(3):462-9. PubMed ID: 20453736
[TBL] [Abstract][Full Text] [Related]
11. Development of Chitosan-Based Hydrogel Containing Antibiofilm Agents for the Treatment of Staphylococcus aureus-Infected Burn Wound in Mice.
Chhibber T; Gondil VS; Sinha VR
AAPS PharmSciTech; 2020 Jan; 21(2):43. PubMed ID: 31897806
[TBL] [Abstract][Full Text] [Related]
12. Influence of intravenous regional limb perfusion with amikacin sulfate on Staphylococcus aureus bioburden in distal limb wounds in horses.
Freeland RB; Morello SL; DeLombaert M; Rajamanickam V
Vet Surg; 2017 Jul; 46(5):663-674. PubMed ID: 28256725
[TBL] [Abstract][Full Text] [Related]
13. [Azlocillin plus amikacin: an alternative therapy for sepsis caused by resistant staphylococci?].
Hernández ME; Ramos MJ; Ferrer NF
Rev Panam Salud Publica; 2004 Nov; 16(5):315-9. PubMed ID: 15729980
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy: a way to limit emergence of resistance?
Michéa-Hamzehpour M; Pechère JC; Marchou B; Auckenthaler R
Am J Med; 1986 Jun; 80(6B):138-42. PubMed ID: 3088999
[TBL] [Abstract][Full Text] [Related]
15. In vitro elution of vancomycin/amikacin/steroid from solvent-free biodegradable scleral plugs.
Liu SJ; Kau YC; Liaw CW; Peng YJ
Int J Pharm; 2009 Mar; 370(1-2):75-80. PubMed ID: 19101617
[TBL] [Abstract][Full Text] [Related]
16. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis.
Dajcs JJ; Moreau JM; Stroman DW; Schlech BA; Ke TL; Thibodeaux BA; Girgis DO; Caballero AR; O'Callaghan RJ
Curr Eye Res; 2001 Jul; 23(1):60-3. PubMed ID: 11821987
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
19. Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system.
Ghazi IM; Grupper M; Nicolau DP
Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):2. PubMed ID: 28095918
[TBL] [Abstract][Full Text] [Related]
20. The use of biodegradable amikacin microspheres to prevent vascular graft infection.
Ney AL; Granja JA; Schuster PA; Tsukayama DT; Jacobs DM; Bubrick MP
J Surg Res; 1994 Dec; 57(6):698-705. PubMed ID: 7996849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
